CRUK
Cancer Research UK, Guardant Health Ink Research, Data Sharing Partnership
The collaboration aims to help accelerate the discovery and development of cancer drugs and diagnostics through ongoing and potentially new clinical trials.
Personalis MRD Assays to Support UK's TRACERx ctDNA Monitoring Study
The ongoing lung cancer study, which has employed other assays in the past, will now use the Personalis NeXT Personal platform to monitor for recurrence after surgery.
AstraZeneca, ArcherDx Partner on Minimal Residual Disease Monitoring for Lung Cancer Drug Trials
ArcherDx will develop sequencing-based circulating tumor DNA assays for use in AstraZeneca's recently launched Phase III MERMAID-1 trial of durvalumab (Imfinzi).
The researchers envisage deploying a point-of-care assay based on a fluorescent nanophotonics platform.
The number of technologies to be assessed is vast, and ranges from liquid biopsies and molecular imaging to immunohistochemistry and RNA-seq.
Nov 30, 2018
Jan 20, 2017